Current choices of antibiotic treatment for Pseudomonas aeruginosa infections

Abstract

Purpose of review Pseudomonas aeruginosa is one of the most feared nosocomial pathogens. Treatment of P. aeruginosa infections is challenging because of the limited choices of antibiotics and the emergent resistance of the pathogen. The present review aims at addressing the management of P. aeruginosa infections and highlighting the novel antibiotics that show a future promising role. Recent findings Novel fluoroquinolones have been recently introduced and show favorable activity. New combinations of b-lactams/b-lactamase inhibitors have been studied in various indications of infections because of P. aeruginosa. Cefiderocol, a new cephalosporin, shows very promising results against P. aeruginosa. Currently, combination therapy is only recommended in limited scenarios. Extended-infusion of b-lactams exhibit clinical benefit. Bacteriophage therapy is a growing field of interest and may have an impactful effect on the treatment of resistant P. aeruginosa. Summary Factors that guide clinical decisions for empiric and directed P. aeruginosa therapy include the epidemiology, the patient’s risk factors, the site of infection, and the available treatment options. Conventional antipseudomonal antibiotics have been used successfully for a long time, but the increase in worldwide resistance necessitates the need for newer agents. Antimicrobial stewardship is essential to preserve the new drugs and prevent future development of resistance. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.